Progressive diffuse large B-cell lymphoma with TP53 gene mutation treated with chidamide-based chemotherapy

Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma

(2018) Valeria Spina et al.   BLOOD

Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma

(2018) David M. Kurtz et al.   JOURNAL OF CLINICAL ONCOLOGY

TP53 mutation and survival in aggressive B cell lymphoma

(2017) Thorsten Zenz et al.   INTERNATIONAL JOURNAL OF CANCER

Thalidomidkezelés relabált, diffúz nagy B-sejtes lymphomában idős betegekben. Három eset bemutatása

(2017) Nikolett Wohner et al.   ORVOSI HETILAP

Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas

(2016) Mary Kwok et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells

(2016) Concepción Fernández-Rodríguez et al.   LEUKEMIA & LYMPHOMA

HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer

(2016) N Stojanovic et al.   ONCOGENE

Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA

(2016) F. Scherer et al.   Science Translational Medicine

Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study

(2016) Dongmei Ji et al.   Oncotarget

Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma

(2015) Y. Shi et al.   ANNALS OF ONCOLOGY

Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non–Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study

(2015) Grzegorz S. Nowakowski et al.   JOURNAL OF CLINICAL ONCOLOGY

Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas

(2015) Clémentine Sarkozy et al.   LANCET ONCOLOGY

Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial

(2014) Umberto Vitolo et al.   LANCET ONCOLOGY

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial

(2013) M Wang et al.   LEUKEMIA

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

(2012) J. G. Lohr et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Analysis of the coding genome of diffuse large B-cell lymphoma

(2011) Laura Pasqualucci et al.   NATURE GENETICS

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

(2010) B. Coiffier et al.   BLOOD

HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells

(2010) R Shimizu et al.   LEUKEMIA

Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: Low-dose metronomic, multidrug therapy

(2008) Morton Coleman et al.   CANCER

Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers ofin vivoresponse

(2008) Jane Houldsworth et al.   LEUKEMIA & LYMPHOMA